Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorates joint swelling in established monkey collagen-induced arthritis

被引：44

作者：

Uchiyama, Yasushi ^{[1
]}

Yorozu, Keigo ^{[1
]}

Hashizume, Misato ^{[1
]}

Moriya, Yoichiro ^{[1
]}

Mihara, Masahiko ^{[1
]}

机构：

[1] Chugai Pharmaceut Co Ltd, Prod Res Dept, Shizuoka 4128513, Japan

来源：

BIOLOGICAL & PHARMACEUTICAL BULLETIN | 2008年 / 31卷 / 06期

关键词：

tocilizumab; therapeutic effect; monkey collagen-induced arthritis;

D O I：

10.1248/bpb.31.1159

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

We examined if tocilizumab, humanized anti-interleukin-6 receptor (IL-6R) antibody, can ameliorate joint swelling after the onset of arthritis in collagen-induced arthritis (CIA). CIA was induced by the immunization of bovine type II collagen in female cynomolgus monkeys. Tocilizumab (30 mg/kg) was administered weekly for 4 weeks after the onset of arthritis. Swelling of 16 proximal interphalangeal (PIP) joints of hands and feet was monitored by, measuring the longitudinal and transverse axes of Pill joints and the oval area of each PIP was calculated. Serum was collected once a week after tocilizumab injection and blood chemistry, IL-6, soluble IL-6R (sIL-6R), and anti-tocilizumab antibody were measured. At the end of study, histopathological examination of joints was performed. Tocilizumab clearly reduced joint swelling in all animals without anti-tocilizumab antibody. Histopathological study showed significant decrease in the infiltration of neutrophils into inflamed joints was observed in tocilizumab-treated animals. In conclusion, tocilizumab improved established arthritis in monkey and monkey CIA model is useful for the analysis of anti-arthritic effect of tocilizumab.

引用

页码：1159 / 1163

页数：5

共 19 条

[1] Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line [J].

Biswas, P ;

Delfanti, F ;

Bernasconi, S ;

Mengozzi, M ;

Cota, M ;

Polentarutti, N ;

Mantovani, A ;

Lazzarin, A ;

Sozzani, S ;

Poli, G .

BLOOD, 1998, 91 (01) :258-265

[2] Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis [J].

Boe, A ;

Baiocchi, M ;

Carbonatto, M ;

Papoian, R ;

Serlupi-Crescenzi, O .

CYTOKINE, 1999, 11 (12) :1057-1064

[3] Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice [J].

Hata, H ;

Sakaguchi, N ;

Yoshitomi, H ;

Iwakura, Y ;

Sekikawa, K ;

Azuma, Y ;

Kanai, C ;

Moriizumi, E ;

Nomura, T ;

Nakamura, T ;

Sakaguchi, S .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :582-588

[4] The point mutation of tyrosine 759 of the IL-6 family cytokine receptor gp130 synergizes with HTLV-1 pX in promoting rheumatoid arthritis-like arthritis [J].

Ishihara, K ;

Sawa, S ;

Ikushima, H ;

Hirota, S ;

Atsumi, T ;

Kamimura, D ;

Park, SJ ;

Murakami, M ;

Kitamura, Y ;

Iwakura, Y ;

Hirano, T .

INTERNATIONAL IMMUNOLOGY, 2004, 16 (03) :455-465

[5] A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].

Ito, H ;

Takazoe, M ;

Fukuda, Y ;

Hibi, T ;

Kusugami, K ;

Andoh, A ;

Matsumoto, T ;

Yamamura, T ;

Azuma, J ;

Nishimoto, N ;

Yoshizaki, K ;

Shimoyama, T ;

Kishimoto, T .

GASTROENTEROLOGY, 2004, 126 (04) :989-996

[6] The importance of IL-1β and TNF-α, and the noninvolvement of IL-6, in the development of monoclonal antibody-induced arthritis [J].

Kagari, T ;

Doi, H ;

Shimozato, T .

JOURNAL OF IMMUNOLOGY, 2002, 169 (03) :1459-1466

[7] Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate [J].

Maini, R. N. ;

Taylor, P. C. ;

Szechinski, J. ;

Pavelka, K. ;

Broell, J. ;

Balint, G. ;

Emery, P. ;

Raemen, F. ;

Petersen, J. ;

Smolen, J. ;

Thomson, D. ;

Kishimoto, T. .

ARTHRITIS AND RHEUMATISM, 2006, 54 (09) :2817-2829

[8] Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family [J].

Mihara, M ;

Kasutani, K ;

Okazaki, M ;

Nakamura, A ;

Kawai, S ;

Sugimoto, M ;

Matsumoto, Y ;

Ohsugi, Y .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2005, 5 (12) :1731-1740

[9] Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys [J].

Mihara, M ;

Kotoh, M ;

Nishimoto, N ;

Oda, Y ;

Kumagai, E ;

Takagi, N ;

Tsunemi, K ;

Ohsugi, Y ;

Kishimoto, T ;

Yoshizaki, K ;

Takeda, Y .

CLINICAL IMMUNOLOGY, 2001, 98 (03) :319-326

[10] THE ESSENTIAL ROLE OF B-CELL STIMULATORY FACTOR-II (BSF-2/IL-6) FOR THE TERMINAL DIFFERENTIATION OF B-CELLS [J].

MURAGUCHI, A ;

HIRANO, T ;

TANG, B ;

MATSUDA, T ;

HORII, Y ;

NAKAJIMA, K ;

KISHIMOTO, T .

JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (02) :332-344

← 1 2 →